2012-12-31
[pdf-embedder url=”http://sheller.com/wp-content/uploads/2015/07/SH_Forbes_Quote_SAS_12_12.pdf”]
A U.S. Appeals Court ruling that pitted free speech rights versus off-label promotion of pharmaceuticals has raised speculation that 2013 may usher in the sort of aggressive marketing by drug makers that has previously drawn the wrath of federal prosecutors.
